Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.
Viking Therapeutics' recent trial results for VK2735 have led to a significant increase in their share price. The company announced plans to raise $275 million through a common stock offering and $225 million via convertible senior notes to fund the development of its drug pipeline. While the trial outcomes are promising and support their VK2735 program, investors should be aware that the study did not involve the oral form of the drug, leaving some uncertainty surrounding its effectiveness.
VK2735 is a GLP-1 and GIP agonist that is being developed to treat obesity and patients with obesity and type 2 diabetes. Following positive Phase 2 data, the drug has progressed to Phase 3 trials in subcutaneous (injectable) form. Management is optimistic about commencing Phase 3 trials for VK2735 in oral form this year. This drug candidate holds two key advantages that could help it establish a profitable niche in the crowded weight-loss treatment market, which is currently dominated by Eli Lilly and Novo Nordisk.
These advantages include superior rapid weight loss observed in Phase 2 trials compared to competitors, as well as a dual formulation strategy. This approach involves an initial rapid weight-loss dose administered in subcutaneous form, followed by more convenient oral dosing of VK2735.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
